Evidence map›Paper›PMID 28572701›Full record

ReviewIndustrial & engineering chemistry research2017

Protease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging.

Caleb F Anderson, Honggang Cui

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Industrial & engineering chemistry research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  6. Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  11. Engineering Targeting Materials for Therapeutic Cancer Vaccines.Frontiers in bioengineering and biotechnology · 2020
    Review
  12. Article
  13. Cancer targeting peptides.Cellular and molecular life sciences : CMLS · 2019
    Review
  14. Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caleb F AndersonDepartment of Chemical and Biomolecular Engineering and Institute for NanoBioTechnology, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States.
Honggang CuiDepartment of Chemical and Biomolecular Engineering and Institute for NanoBioTechnology, Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States.
Johns Hopkins University · US

Funding

Camptothecin Transformative Nanotubes as Effective Drug CarriersR21CA191740 · NCI · JOHNS HOPKINS UNIVERSITY · PI CUI, HONGGANG · 2015 to 2016
$377k
NCI NIH HHS R21 CA191740
6 · The paper itself

Abstract

Many diseases can be characterized by the abnormal activity exhibited by various biomolecules, the targeting of which can provide therapeutic and diagnostic utility. Recent trends in medicine and nanotechnology have prompted the development of protease-sensitive nanomaterials systems for therapeutic, diagnostic, and theranostic applications. These systems can act specifically in response to the target enzyme and its associated disease conditions, thus enabling personalized treatment and improved prognosis. In this Review, we discuss recent advancements in the development of protease-responsive materials for imaging and drug delivery and analyze several representative systems to illustrate their key design principles.

Identifiers

PMID28572701
PMCPMC5445504
OpenAlexW2609041775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.